BioInvent International (BINV) Jefferies Global Healthcare Conference 2025 summary

Company overview and platform

• Integrated immuno-oncology company with in-house target discovery, antibody development, manufacturing, and clinical programs; currently running six clinical programs with five compounds in various stages, focusing on phase two leads.

• Strong international shareholder base, with major investors controlling 65% and recent $20M upfront from a royalty deal extending cash runway to end of next year.

• Proprietary FIRST platform enables direct screening on patient tumor material, identifying novel IO targets and functional epitopes.

• Portfolio includes differentiated anti-CTLA4, TNFR2, and FcγR2B programs, with main focus on TNFR2 and FcγR2B.

• All assets developed internally, with only one license agreement for BI-1206 in China, Hong Kong, and Macau; extensive collaborations with Merck and AstraZeneca are supply-only.

Lead clinical programs and data highlights

• BL-1808 (TNFR2) is a first-in-class ligand-blocking antibody showing strong efficacy and safety in phase two, with promising results in CTCL, ovarian, lung, and GIST cancers.

• CTCL program received orphan drug and fast track designations; monotherapy shows ~40-50% response rate and excellent safety, positioning as a potential frontline treatment.

• Solid tumor studies show single-agent activity and robust immune activation, with some patients achieving complete responses.

• BI-1206 (FcγR2B) is a monospecific antibody targeting resistance to anti-CD20 therapy in non-Hodgkin lymphoma, showing high response rates and durable complete responses, including >3 years in some patients.

• Triplet study with BI-1206, rituximab, and acalabrutinib in collaboration with AstraZeneca shows 100% disease control in first eight patients, with no toxicity.

Development plans and upcoming milestones

• Pivotal phase 2 for BI-1206 in follicular lymphoma planned for next year, with regulatory discussions supporting approval based on pivotal phase 2 data.

• Ongoing studies in solid tumors for BI-1206, focusing on patients resistant to anti-PD1/PDL1, with robust and durable responses observed.

• Expansion of clinical sites in the US and Europe for all major programs, with site selection based on recruitment speed.

• Key catalysts for 2024 include updated BL-1808 CTCL data, triplet combination data, and first data sets for BL-1910 and BL-1607 by year-end.

• All preclinical and much of the clinical work is performed in-house, leveraging extensive internal expertise and resources.